Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Dongwook Oh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6084-0138; OpenAlex author ID A5010892652. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 0, last author 1)
Trials
1
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 4 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 trial · 2026: 3 papers

Papers 15

  1. Comparison of clinical features and pancreatic cancer risk between genetic mutations associated versus alcohol associated chronic pancreatitis. Co-author DOI 10.1016/j.pan.2025.10.011↗
  2. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  3. A Clinical Score to Identify Individuals at High Risk of Pancreatic Cancer in the General Population. Co-author DOI 10.3390/diagnostics16152390↗
  4. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Co-author DOI 10.1016/j.ejca.2024.114194↗
  5. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  6. Acute pancreatitis as an early sign of pancreatic cancer; a retrospective, matched cohort study. Last author DOI 10.1080/00365521.2024.2414804↗
  7. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  8. The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks? Co-author DOI 10.1007/s00464-021-08627-3↗
  9. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  10. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  11. Clinical outcomes of EUS-guided radiofrequency ablation for unresectable pancreatic cancer: A prospective observational study. Co-author DOI 10.4103/eus-d-21-00049↗
  12. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
  13. Prognostic Roles of Inflammatory Markers in Pancreatic Cancer: Comparison between the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Co-author DOI 10.1155/2018/9745601↗
  14. Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer. Co-author DOI 10.5009/gnl17391↗
  15. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2015.08.048↗

Trials 1

  1. Efficacy and Safety of HANAROSTEN® HOT Plumber™ With Z-EUSIT™ for Pancreatic Pseudocyst Drainage Study director NCT06855485↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tae Jun Song · 13 shared papers, 2016–2026 · strength 2.16
  2. Changhoon Yoo · 8 shared papers, 2020–2026 · strength 1.30
  3. Dong Wan Seo · 8 shared papers, 2016–2026 · strength 1.28
  4. Do Hyun Park · 10 shared papers, 2016–2024 · strength 1.28
  5. Kyu‐pyo Kim · 7 shared papers, 2020–2026 · strength 1.07
  6. Baek‐Yeol Ryoo · 7 shared papers, 2020–2026 · strength 1.07
  7. Sang Soo Lee · 8 shared papers, 2016–2024 · strength 0.91
  8. Jin‐hong Park · 6 shared papers, 2020–2026 · strength 0.89
  9. Hyehyun Jeong · 4 shared papers, 2024–2026 · strength 0.82
  10. Ki Byung Song · 5 shared papers, 2022–2026 · strength 0.81
  11. Dae Wook Hwang · 5 shared papers, 2022–2026 · strength 0.81
  12. Song Cheol Kim · 5 shared papers, 2022–2026 · strength 0.81
  13. Myung‐Hwan Kim · 6 shared papers, 2016–2022 · strength 0.67
  14. Inkeun Park · 3 shared papers, 2024–2026 · strength 0.60
  15. Gunn Huh · 2 shared papers, 2024–2026 · strength 0.58
  16. Yoonchan Lee · 2 shared papers, 2024–2026 · strength 0.58
  17. Woohyung Lee · 3 shared papers, 2022–2026 · strength 0.51
  18. Bong Jun Kwak · 3 shared papers, 2022–2024 · strength 0.42
  19. Dong‐Wan Seo · 2 shared papers, 2022 · strength 0.31
  20. Yejong Park · 2 shared papers, 2023–2024 · strength 0.30
  21. Hyo Jeong Lee · 1 shared paper, 2026 · strength 0.28
  22. Ji Young Lee · 1 shared paper, 2026 · strength 0.28
  23. Sung‐Hoon Moon · 2 shared papers, 2018–2024 · strength 0.26
  24. So Heun Lee · 2 shared papers, 2022–2023 · strength 0.26
  25. Seung Soo Lee · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.